MFSD10: A Potential Drug Target for various Diseases (G10227)

Target Name: MFSD10

NCBI ID: G10227

MFSD10

MFSD10: A Potential Drug Target for various Diseases

MFSD10, also known as MFSD10 variant 1, is a gene that has been identified as a potential drug target for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The MFSD10 gene is a member of the microsatellite family, which are a common genetic cause of human diseases.

MFSD10 is a single exon gene that encodes a protein known as MFSD10. The protein produced by MFSD10 has several unique features that make it a potential drug target. One of these features is its ability to interact with various signaling pathways, including NF-kappa, NF-kappa-B, and PI3K/AKT. This interactivity suggests that MFSD10 may be involved in the regulation of cellular processes that are important for human health and disease.

Another potential drug target for MFSD10 is its role in the development of cancer. MFSD10 has been shown to be highly expressed in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, studies have suggested that MFSD10 may be involved in the regulation of cell proliferation and the development of cancer stem cells. This involvement makes MFSD10 an attractive target for cancer therapies that aim to inhibit cell proliferation or promote cell death.

MFSD10 has also been shown to be involved in the regulation of neurodegenerative diseases. For example, MFSD10 has been shown to be expressed in the brains of individuals with Alzheimer's disease, and studies have suggested that it may be involved in the development and progression of this disease. Additionally, MFSD10 has been shown to interact with a protein called TrkB, which is involved in the regulation of neurotransmitter release and is thought to play a role in the development of other neurodegenerative diseases.

Finally, MFSD10 has also been shown to be involved in the regulation of autoimmune disorders. For example, MFSD10 has been shown to be expressed in the immune cells of individuals with rheumatoid arthritis, and studies have suggested that it may be involved in the development and regulation of autoimmune disorders. Additionally, MFSD10 has been shown to interact with a protein called ITGA3, which is involved in the regulation of cellular signaling pathways that are important for immune function.

In conclusion, MFSD10 is a gene that has been identified as a potential drug target for the treatment of various diseases. Its unique interactions with signaling pathways and its involvement in the regulation of cellular processes that are important for human health and disease make it an attractive target for therapies that aim to inhibit cell proliferation, promote cell death, and regulate neurotransmitter release and immune function. Further research is needed to fully understand the role of MFSD10 in disease and to develop effective therapies that target this gene.

Protein Name: Major Facilitator Superfamily Domain Containing 10

Functions: Probable organic anion transporter which may serve as a transporter for some non-steroidal anti-inflammatory drugs (NSAIDs) as well as other organic anions across the luminal membranes of renal proximal tubules at the final excretion step into the urine

The "MFSD10 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MFSD10 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets